Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia

Muhammad Rizwan Khawaja, Susan M. Perkins, Jennifer E. Schwartz, Michael J. Robertson, Patrick J. Kiel, Hamid Sayar, Elizabeth A. Cox, Gail H. Vance, Sherif S. Farag, Larry D. Cripe, Robert P. Nelson

Research output: Contribution to journalArticlepeer-review

Abstract

We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have secondary AML and lower performance status. At a median follow-up of 61 months, median event-free survival and overall survival survival were not different between NMAT and MAT in univariate as well as multivariate analyses. Cy/Flu NMAT may provide similar disease control and survival when compared with MAT in patients with AML in remission or without frank relapse. Am. J. Hematol. 90:97-99, 2015.

Original languageEnglish (US)
Pages (from-to)97-99
Number of pages3
JournalAmerican Journal of Hematology
Volume90
Issue number2
DOIs
StatePublished - Feb 1 2015

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this